Cervical cancer remains a significant health burden worldwide, particularly for patients with elevated pretreatment serum squamous cell carcinoma antigen (SCC-Ag) levels. To address this clinical challenge, researchers developed a cervical cancer prognostic nomogram to improve outcome predictions for high-risk individuals. This model integrates specific clinical factors and inflammatory biomarkers to offer a more personalized approach to patient management and care.

Identifying Independent Prognostic Factors

The study analyzed clinical characteristics and hematological indices in 355 patients receiving radiotherapy. The results demonstrated that the hemoglobin-to-red cell distribution width ratio (HRR) and the neutrophil-to-lymphocyte ratio (NLR) serve as critical markers. Furthermore, clinical stage and treatment modality also significantly influence survival outcomes. By combining these variables, clinicians can more accurately estimate the overall survival rates at one, two, and three years for patients with SCC-Ag levels ≥ 10 ng/mL.

Clinical Utility of the Cervical Cancer Prognostic Nomogram

Validation of the model demonstrated a concordance index of 0.729 in the training cohort, which indicates strong predictive reliability. Additionally, decision curve analysis confirmed that this tool provides a consistent net clinical benefit for oncology professionals. Consequently, the nomogram allows for effective risk stratification, distinguishing between high- and low-risk groups. This stratification helps oncologists tailor treatment strategies more precisely for each individual patient based on their unique inflammatory and clinical profile.

Frequently Asked Questions

What inflammatory markers are used in this nomogram?

The model utilizes the hemoglobin-to-red cell distribution width ratio (HRR) and the neutrophil-to-lymphocyte ratio (NLR) as key inflammatory predictors for survival outcomes.

How accurate is the cervical cancer prognostic nomogram?

The nomogram achieved a concordance index of approximately 0.70 to 0.73. It also showed favorable area under the curve (AUC) values for survival prediction at 1, 2, and 3 years in both training and validation cohorts.

Why is SCC-Ag ≥ 10 ng/mL significant?

Patients with SCC-Ag levels at or above 10 ng/mL typically experience poorer outcomes, making them a high-risk group that requires more precise prognostic tools for treatment planning.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Zhao Y et al. Prognostic prediction in primary cervical squamous cell carcinoma with serum squamous cell carcinoma antigen ≥ 10 ng/mL: development and validation of a nomogram model based on inflammatory biomarkers and clinical factors. BMC Cancer. 2026 Mar 07. doi: 10.1186/s12885-026-15824-7. PMID: 41795093.

Smith A et al. Role of inflammatory biomarkers in gynecological malignancies. Journal of Clinical Oncology Research. 2024;12(4):210-218.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 1.2025.